Lilly (Eli) vs Shopify

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (88 vs 86)
Lilly (Eli) logo

Lilly (Eli)

LeaderHealthcare Tech

Enterprise

Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A88
Category Rank
#125 of 290
AI Consensus
51%
Trend
stable
Per Platform
ChatGPT
89
Perplexity
79
Gemini
99

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.

Full profile
Shopify logo

Shopify

LeaderE-commerce

E-commerce Platform

NYSE: SHOP e-commerce platform at $8.88B FY2024 revenue with $292.28B GMV across 4.82M stores; Black Friday $11.5B processing competing with WooCommerce and BigCommerce for small-to-enterprise direct-to-consumer commerce.

AI VisibilityBeta
Overall Score
A86
Category Rank
#1 of 3
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
89
Gemini
91

About

Shopify Inc. is an Ottawa, Canada-based e-commerce platform — listed on NYSE (NYSE: SHOP) — providing 4.82+ million active merchant stores of all sizes (from solo entrepreneurs to enterprise brands) with tools for online store creation, multi-channel selling (web, mobile, social, in-person), payment processing (Shopify Payments, Shop Pay), inventory management, fulfillment, and marketing analytics, generating $8.88 billion in revenue in fiscal year 2024 (+26% year-over-year) with $292.28 billion in gross merchandise volume (GMV, +24%) and 875+ million customers who have purchased from Shopify merchant stores. Founded in 2006 by Tobias Lütke, Daniel Weinand, and Scott Lake (started as a snowboard equipment store, pivoted to become the platform), Shopify has become the operating system for independent commerce — the default e-commerce infrastructure for the direct-to-consumer brand economy.

Full profile

AI Visibility Head-to-Head

88
Overall Score
86
#125
Category Rank
#1
51
AI Consensus
71
stable
Trend
stable
89
ChatGPT
84
79
Perplexity
89
99
Gemini
91
90
Claude
79
80
Grok
88

Key Details

Category
Enterprise
E-commerce Platform
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Shopify
E-commerce Platform
Lilly (Eli) is classified as company. Shopify is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.